DE69814618T2 - Behandlung von infarkten durch inhibierung von nf-kappab - Google Patents

Behandlung von infarkten durch inhibierung von nf-kappab Download PDF

Info

Publication number
DE69814618T2
DE69814618T2 DE69814618T DE69814618T DE69814618T2 DE 69814618 T2 DE69814618 T2 DE 69814618T2 DE 69814618 T DE69814618 T DE 69814618T DE 69814618 T DE69814618 T DE 69814618T DE 69814618 T2 DE69814618 T2 DE 69814618T2
Authority
DE
Germany
Prior art keywords
use according
inhibitor
inhibitors
activation
proteasome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69814618T
Other languages
German (de)
English (en)
Other versions
DE69814618D1 (de
Inventor
Stephen Brand
L. Alfred GOLDBERG
Louis Plamondon
François SOUCY
Peter J. Elliot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of DE69814618D1 publication Critical patent/DE69814618D1/de
Application granted granted Critical
Publication of DE69814618T2 publication Critical patent/DE69814618T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
  • Artificial Filaments (AREA)
  • Transplanting Machines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69814618T 1997-02-15 1998-02-17 Behandlung von infarkten durch inhibierung von nf-kappab Expired - Lifetime DE69814618T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80193697A 1997-02-15 1997-02-15
US98833997A 1997-12-03 1997-12-03
US988339 1997-12-03
PCT/US1998/003077 WO1998035691A1 (en) 1997-02-15 1998-02-17 Treatment of infarcts through inhibition of nf-kappab
US801936 2001-03-08

Publications (2)

Publication Number Publication Date
DE69814618D1 DE69814618D1 (de) 2003-06-18
DE69814618T2 true DE69814618T2 (de) 2004-03-25

Family

ID=27122399

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69814618T Expired - Lifetime DE69814618T2 (de) 1997-02-15 1998-02-17 Behandlung von infarkten durch inhibierung von nf-kappab

Country Status (14)

Country Link
US (3) US6271199B2 (cg-RX-API-DMAC10.html)
EP (1) EP0979096B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001511814A (cg-RX-API-DMAC10.html)
CN (1) CN1159061C (cg-RX-API-DMAC10.html)
AT (1) ATE240113T1 (cg-RX-API-DMAC10.html)
AU (1) AU741802B2 (cg-RX-API-DMAC10.html)
CA (1) CA2281224A1 (cg-RX-API-DMAC10.html)
DE (1) DE69814618T2 (cg-RX-API-DMAC10.html)
ES (1) ES2196547T3 (cg-RX-API-DMAC10.html)
IL (1) IL131410A0 (cg-RX-API-DMAC10.html)
NO (1) NO321203B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ337364A (cg-RX-API-DMAC10.html)
PT (1) PT979096E (cg-RX-API-DMAC10.html)
WO (1) WO1998035691A1 (cg-RX-API-DMAC10.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1008352A4 (en) * 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Cerebrospinal PROTECTOR
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US20090042807A1 (en) * 1998-05-20 2009-02-12 Nisar Ahmed Khan Oligopeptide treatment of ischemia reperfusion injury
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
WO2001019376A2 (en) * 1999-09-13 2001-03-22 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
ES2402045T3 (es) * 2000-11-16 2013-04-26 The Regents Of The University Of California Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
ES2278049T3 (es) 2001-05-21 2007-08-01 Alcon, Inc. Uso de inhibidores de proteasoma para tratar trastornos de ojo seco.
BR0213100A (pt) * 2001-10-05 2004-11-30 Combinatorx Inc Combinações para o tratamento de distúrbios imuniinflamatórios
WO2003053425A1 (en) * 2001-12-10 2003-07-03 Yansheng Du Treatment of neurodegenerative and cardiovascular disorders
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
JP2007523862A (ja) * 2003-06-20 2007-08-23 ネレアス ファーマシューティカルズ インコーポレイテッド 癌、炎症及び感染性疾患の治療のための、[3.2.0]複素環式化合物およびそれらの類縁体の使用
US8217072B2 (en) * 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7348305B2 (en) * 2003-08-28 2008-03-25 Department Of Veterans Affairs, Rehabilitation Inhibitor of cardiac tachyarrhythmias
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7276530B2 (en) * 2004-04-30 2007-10-02 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7425580B2 (en) * 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
US20060008454A1 (en) * 2004-07-07 2006-01-12 Dr. Helmut Brunar Use of a compound for enhancing the expression of membrane proteins on the cell surface
WO2006002453A2 (en) * 2004-07-07 2006-01-12 Biodevelops Pharma Entwicklung Gmbh Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface
CN101010334B (zh) * 2004-08-30 2013-02-06 东丽株式会社 分级装置
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
CN103230394B (zh) 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
WO2007002972A2 (en) * 2005-07-06 2007-01-11 Biodevelops Pharma Entwicklung Gmbh Use of a compound for enhancing the expression of membrane proteins on the cell surface
US20070015777A1 (en) * 2005-07-14 2007-01-18 Myogen, Inc. Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
US7691896B2 (en) * 2005-08-10 2010-04-06 President And Fellows Of Harvard College Analogs of salinosporamide A
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
ES2293834B1 (es) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
DK2120991T3 (da) * 2007-02-12 2014-04-28 Biotempt Bv Behandling af traumatisk blødning med korte oligopeptider
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
US7910616B2 (en) 2008-05-12 2011-03-22 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
EP2527434B1 (en) 2010-01-22 2017-08-09 Japan Science and Technology Agency Probe reagent for measurement of proteolytic activity
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
BR112014028094B1 (pt) 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
US10023611B2 (en) 2013-04-16 2018-07-17 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN106132970B (zh) 2014-02-03 2020-09-04 俄亥俄州创新基金会 硼酸酯和其药物制剂
UA121389C2 (uk) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
JP2018510859A (ja) 2015-03-17 2018-04-19 レオン−ナノドラッグズ ゲーエムベーハー 安定化されたボロン酸化合物を含むナノ粒子
US11897969B2 (en) 2017-10-26 2024-02-13 The Regents Of The University Of California Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT62312A (en) 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
DE69636997T2 (de) * 1995-05-12 2007-07-12 Anges MG Inc., Ibaraki HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
US5942494A (en) 1995-10-06 1999-08-24 The Trustees Of Columbia University In The City Of New York Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
ATE265537T1 (de) 1996-03-19 2004-05-15 Millennium Pharm Inc Kinase für die stellen-spezifische phosphorylierung von i-kappa-b-alpha
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof

Also Published As

Publication number Publication date
US20010053760A1 (en) 2001-12-20
HK1025266A1 (en) 2000-11-10
DE69814618D1 (de) 2003-06-18
CA2281224A1 (en) 1998-08-20
ATE240113T1 (de) 2003-05-15
US20030069189A1 (en) 2003-04-10
NO993935D0 (no) 1999-08-16
CN1159061C (zh) 2004-07-28
JP2001511814A (ja) 2001-08-14
EP0979096A1 (en) 2000-02-16
NZ337364A (en) 2001-06-29
CN1250376A (zh) 2000-04-12
NO993935L (no) 1999-10-04
EP0979096B1 (en) 2003-05-14
PT979096E (pt) 2003-09-30
AU6171998A (en) 1998-09-08
NO321203B1 (no) 2006-04-03
US20010002391A1 (en) 2001-05-31
AU741802B2 (en) 2001-12-13
WO1998035691A1 (en) 1998-08-20
US6271199B2 (en) 2001-08-07
IL131410A0 (en) 2001-01-28
ES2196547T3 (es) 2003-12-16

Similar Documents

Publication Publication Date Title
AU741802B2 (en) Treatment of infarcts through inhibition of NF-kappaB
WO1998035691A9 (en) Treatment of infarcts through inhibition of nf-kappab
DE68916387T2 (de) Verwendung von Nalmefen oder Naltrexon bei der Behandlung von Autoimmunerkrankungen.
DE69636308T2 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
DE69028542T2 (de) Felbamat zur Behandlung der Lennox-Gastaut syndrome
Novak et al. Effects of a single large intravenous dose of methylprednisolone sodium succinate
US5310562A (en) Composition and method for reparation and prevention of fibrotic lesions
DE69130289T2 (de) Therapeutische verwendung von actin-bindenden verbindungen
EP0458861B1 (en) Composition for reparation and prevention of fibrotic lesions
DE69711649T2 (de) P1, p4-dithio-p2,p3-monochloromethylen 5',5'''-diadenosin-p1,p4-tetraphosphat verwendet als anti-thrombose mittel
DE69506197T2 (de) Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis
Borel Effect of some drugs on the chemotaxis of rabbit neutrophils in vitro
Konishi et al. Carbamazepine-induced skin rash in children with epilepsy
Lauerma et al. Topical FK506–clinical potential or laboratory curiosity?
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
DE69413090T2 (de) Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel
DE60026491T2 (de) Melagatran zur behandlung von entzündungen
Dow et al. The effects of some anticonvulsant drugs on cobalt‐induced epilepsy
EP0461499A2 (de) Verwendung der Efomycine A,E und G als entzündungshemmende Mittel
EP1001756B1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
Pumain Electrophysiological abnormalities in chronic epileptogenic foci: an intracellular study
DE69903964T2 (de) Chemokin rezeptor antagonist und cyclosporin in kombinationstherapie
DE3888144T2 (de) Gehirn-Neuron schützendes Mittel, enthaltend eine Dihydropyridin-Verbindung.
DE60103857T2 (de) Verwendung von indoloquinoxalinen zur behandlung der multiplen sklerose
DE19711795C2 (de) Verwendung von Cyclosporin für die Behandlung von Myokardinfarkten und deren Folgen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition